AN2 Therapeutics Inc (ANTX)
2.255
-0.02
(-0.66%)
USD |
NASDAQ |
May 16, 16:00
2.255
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Cash from Investing (Quarterly): 26.29M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 26.29M |
| December 31, 2023 | 0.42M |
| September 30, 2023 | -62.46M |
| June 30, 2023 | 7.877M |
| March 31, 2023 | 10.89M |
| December 31, 2022 | 6.055M |
| September 30, 2022 | -2.317M |
| Date | Value |
|---|---|
| June 30, 2022 | -39.49M |
| March 31, 2022 | 13.98M |
| December 31, 2021 | 6.246M |
| September 30, 2021 | -6.986M |
| June 30, 2021 | -49.28M |
| March 31, 2021 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-62.46M
Minimum
Sep 2023
26.29M
Maximum
Mar 2024
-6.830M
Average
0.42M
Median
Dec 2023
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences Inc | -2.207B |
| QuidelOrtho Corp | -20.20M |
| CymaBay Therapeutics Inc (DELISTED) | -42.11M |
| Insmed Inc | 295.32M |
| Revance Therapeutics Inc | -31.71M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.59M |
| Cash from Financing (Quarterly) | 0.349M |
| Free Cash Flow | -59.28M |
| Free Cash Flow Per Share (Quarterly) | -0.5911 |
| Free Cash Flow Yield | -100.4% |